The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a $135,246,410.19 cost-sharing definitive contract to Basilea Pharmaceutica International Ltd, doing business as Basilea Pharmaceutica International SA, for the advanced development of the antibiotic ceftobiprole. This contract, which does not have a set-aside designation, aims to support the development of innovative antibiotics to combat multidrug-resistant bacteria, particularly gram-negative pathogens. Basilea, a biopharmaceutical company specializing in developing novel antibiotics, is conducting research and development on two key projects: disrupting the lipopolysaccharide transport in gram-negative bacteria and developing inhibitors of an essential enzyme not targeted by current antibiotics. This work aligns with the agency's priority to address urgent global health threats posed by serious bacterial infections. The contract is being administered through a sub-award with the Trustees of Boston University as the prime contractor.
Generated 9/26/24, 9:44 AM